The immature platelet fraction (%IPF) is a highly utilised new parameter in the full blood count (FBC) profile. It is a measure of the number of reticulated platelets and hence provides information on platelet transfusion requirements. It is common practice to measure %IPF values on blood samples that are several hours old, however unlike the well known good stability of other well established and more traditional FBC parameters such as haemoglobin and platelet counts, previous animal studies have shown that reticulated platelets are unstable. This study therefore assessed the validity of %IPF values obtained from stored patient samples. Our findings showed that %IPF values alter with storage; significant differences in %IPF values were obtained on stored samples compared with freshly analysed samples (p<0.001). It is therefore essential that in order to maintain the clinical utility of the %IPF, analyses should only be made on freshly drawn blood samples.
Download full-text PDF |
Source |
---|---|
http://dx.doi.org/10.1179/102453309X385098 | DOI Listing |
Front Med (Lausanne)
January 2025
Department of Respiratory and Critical Care Medicine, The Second Affiliated Hospital of Xi'an Jiaotong University, Xi'an, China.
Background: Idiopathic pulmonary fibrosis (IPF) is an interstitial lung disease characterized by chronic inflammation and progressive fibrosis. The blood urea nitrogen-to-albumin ratio (BAR) is a comprehensive parameter associated with inflammation status; however, it is unknown whether the BAR can predict the prognosis of IPF.
Methods: This retrospective study included 176 patients with IPF, and 1-year all-cause mortality of these patients was recorded.
J Thorac Dis
December 2024
Department of Respiratory Medicine, the First Affiliated Hospital of Henan University of Traditional Chinese Medicine, Zhengzhou, China.
Background: Idiopathic pulmonary fibrosis (IPF) has high mortality and poor prognosis, which brings enormous burdens to families and society. We conducted this meta-analysis to analyze and summarize the risk factors associated with mortality in IPF, hoping to provide reference for clinical prevention and treatment of IPF.
Methods: We conducted a comprehensive search of PubMed, Cochrane Library, Embase, and Web of Science from inception to August 10, 2023, to include cohort studies on mortality in patients with IPF.
Immun Inflamm Dis
January 2025
Department of Medical and Surgical Sciences & Neurosciences, Respiratory Diseases Unit, Siena University Hospital, Siena, Tuscany, Italy.
Background: Post-coronavirus disease 19 lung fibrosis (PCLF) shares common immunological abnormalities with idiopathic pulmonary fibrosis (IPF), characterized by an unbalanced cytokine profile being associated with the development of lung fibrosis. The aim of the present study was to analyze and compare the different subsets of CD4- and CD8-T cells, along with specific cytokine expression patterns, in peripheral blood (PB) from patients affected by PCLF and IPF and healthy controls (HCs).
Methods: One-hundred patients followed at the Rare Lung Disease Center of Siena University Hospital were enrolled.
Sci Rep
January 2025
Department of Diagnostic and Interventional Radiology, University Hospital Bonn, Venusberg-Campus 1, 53127, Bonn, Germany.
Automated tools for quantification of idiopathic pulmonary fibrosis (IPF) can aid in ensuring reproducibility, however their complexity and costs can differ substantially. In this retrospective study, two automated tools were compared in 45 patients with biopsy proven (12/45) and imaging-based (33/45) IPF diagnosis (mean age 74 ± 9 years, 37 male) for quantification of pulmonary fibrosis in CT. First, a tool that identifies multiple characteristic lung texture features was applied to measure multi-texture fibrotic lung (MTFL) by combining the amount of ground glass, reticulation, and honeycombing.
View Article and Find Full Text PDFPharmaceuticals (Basel)
November 2024
Department of Pharmaceutics and Industrial Pharmacy, Faculty of Pharmacy, Beni-Suef University, Beni-Suef 62514, Egypt.
: Idiopathic pulmonary fibrosis (IPF) is a prevalent interstitial lung disease that typically progresses gradually, leading to respiratory failure and ultimately death. IPF can be treated with the tyrosine kinase inhibitor, nintedanib (NTD), owing to its anti-fibrotic properties, which ameliorate the impairment of lung function. This study aimed to formulate, optimize, and assess NTD-loaded ufasomes (NTD-UFSs) as a nanosystem for its pulmonary targeting to snowball the bioavailability and therapeutic efficacy of the drug.
View Article and Find Full Text PDFEnter search terms and have AI summaries delivered each week - change queries or unsubscribe any time!